Premium
Antiplatelet therapies in diabetes
Author(s) -
Sagar R. C.,
Naseem K. M.,
Ajjan R. A.
Publication year - 2020
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.14291
Subject(s) - medicine , diabetes mellitus , intensive care medicine , endocrinology
Cardiovascular complications remain the main cause of mortality and morbidity in diabetes. This is related to advanced vascular pathology in this population, together with an enhanced thrombotic environment. The increased risk in thrombosis is secondary to platelet hyper‐reactivity and increased levels and/or altered activity of coagulation factors. The current review is focused on the role of antiplatelet agents in modulating the thrombotic milieu in diabetes and improving vascular outcome in this high‐risk population. We review the latest evidence for the use of aspirin in primary vascular prevention together with long‐term treatment with this agent for secondary prevention. We also discuss the effects of the various P2Y 12 inhibitors, including clopidogrel, prasugrel and ticagrelor, on both short‐ and long‐term secondary vascular prevention. Moreover, we briefly review antiplatelet therapies in special groups of people including those intolerant to aspirin, individuals with peripheral vascular disease and those with cerebrovascular pathology. The overall aim of this review is to provide the healthcare professional with a pragmatic guide for the management of thrombotic risk using established antiplatelet therapies to improve vascular outcome in persons with diabetes.